KRAS and non-small cell lung carcinoma: Genetic characterization of oncogenic driver mutations (EGFR, KRAS, ALK, ROS) has transformed the management of non-small cell lung cancer (NSCLC) therapy with the introduction of molecularly targeted therapies, allowing an individualized treatment approach [2, 3].